1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability

 
• By Joseph Haas

Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.

Cystic Fibrosis
Vertex develops and markets therapies addressing the underlying cause of CF

Vertex Pharmaceuticals Inc. has decided to use its next-generation CFTR corrector VX-445 as the third component of its triple therapy regimen for cystic fibrosis, choosing that compound over VX-659 mainly on considerations of safety and tolerability. The Boston-area firm now plans to file its triple regimen for US approval in the third quarter and for European approval in the fourth quarter.

Already the dominant player in cystic fibrosis due to therapies that address the disease’s underlying cause by increasing and/or improving...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.